Losing weight on a GLP-1? Your muscle is the part worth protecting.
The medication isn't what costs you lean mass. How steep your deficit runs and how hard you train are — and both of those are decisions, not side effects.
The question everyone asks first
"Will I lose muscle on this?" It's the right question, and the honest answer has more in it than a yes or a no.
Any meaningful weight loss costs you some lean tissue. That's true of a GLP-1, and it's equally true of a diet you run on willpower alone. Weight loss is never purely fat — the body gives up some muscle, some glycogen, some water alongside it. That is a feature of being in a calorie deficit, not a feature of any particular drug.
What matters is proportion. Two people can lose the same twenty pounds: one arrives lean and strong, the other arrives smaller and softer with a slower metabolism than they started with. Same scale movement, completely different outcome.
The mechanism people get wrong: these medications don't attack muscle tissue. They reduce appetite. That's the whole effect — the drug makes it far easier to stay in a deficit than willpower ever did.
Which is exactly where the trouble starts. It removes the thing that used to stop people from cutting too hard.
So why do people on GLP-1s look like they lost muscle?
Because a lot of them did. Not from the drug — from how they used it.
The deficit gets too steep
Hunger is a brake. It's uncomfortable, but it stops most people from running a 1,200-calorie day for months. Take that brake off and appetite suppression can drive intake far below what the body needs to hold onto tissue. People aren't choosing an aggressive cut; they simply stop feeling like eating and never notice how low they've gone.
The faster the scale drops, the larger the share of that loss that comes from lean tissue. This is the single biggest lever, and almost nobody is monitoring it.
Protein falls off a cliff
Reduced appetite doesn't cut evenly across the plate. Protein is filling and, for a lot of people on these medications, becomes actively unappealing. Carbohydrate and fat intake tend to hold up better. So total intake drops and the protein share of it drops further — right when the body most needs the raw material to defend muscle.
Nothing is asking the muscle to stay
The body is efficient. Muscle is metabolically expensive to maintain, so in a deficit it will shed anything it isn't using. Resistance training is the signal that says this tissue is load-bearing, keep it. Without that signal, in a deficit, muscle is overhead the body will happily cut.
Weight loss without training is a request to get smaller. The body honours it — everywhere, not just in fat.
What the numbers look like when nobody trains
This isn't theoretical. The body composition data from the major trials tells you exactly what happens when weight comes off without a training stimulus underneath it.
STEP 1 — semaglutide
The landmark semaglutide trial ran 68 weeks in nearly 2,000 adults and produced roughly 15% mean weight loss. The DXA substudy separated what came off: total fat mass fell 19.3%, and lean body mass fell 9.7%. Run the ratio and lean tissue accounted for close to four in every ten pounds lost.
For comparison, a straightforward calorie deficit without medication typically runs closer to 75% fat and 25% lean. Trial participants weren't following a training programme.
The rest of the class
- Tirzepatide came in around 25% lean on DXA — roughly the same as dieting alone.
- Retatrutide's body composition substudy showed lean loss in line with total weight loss, with no sign of drug-specific muscle catabolism.
- Across the wider trial landscape, the figures cluster near that same 25% baseline. STEP 1's 38% sits high rather than typical.
One honest caveat, because it matters for reading any of these numbers: "lean mass" on a DXA scan is not the same thing as muscle. It captures water, glycogen, organ tissue and liver fat alongside skeletal muscle. Since these drugs produce large reductions in liver fat, some of what registers as lean loss on the scan is liver, not biceps. The scan overstates muscle loss to a degree nobody can precisely quantify.
What that costs you downstream
Losing a third to two-fifths of your weight as lean tissue isn't a cosmetic problem. It compounds.
- Your maintenance intake drops. Muscle is metabolically active. Less of it means a lower resting expenditure, so you have to eat less than before just to hold your new weight. You've made the rest of your life harder.
- You arrive smaller, not leaner. The soft, deflated result people describe after rapid medicated weight loss is muscle loss, not fat that hasn't finished leaving.
- Regain comes back as fat. Weight regain after stopping is well documented. Regained weight is overwhelmingly fat, so a lose-regain cycle without training ratchets body composition worse each pass.
- Function declines. Strength, bone density and everyday physical capacity track lean mass. In older clients this is the difference between weight loss that improves health and weight loss that quietly undermines it.
Retatrutide: what it is, and what the data actually says
Retatrutide is the compound generating most of the current conversation. It's an investigational molecule from Eli Lilly, and the reason it draws attention is mechanical: where semaglutide targets one receptor and tirzepatide targets two, retatrutide targets three.
The third receptor is the story
It acts on the GLP-1 and GIP receptors — the same pathways as the current generation — and adds glucagon receptor agonism. That addition changes the shape of the effect. GLP-1 and GIP activity works mainly by reducing how much you eat. Glucagon receptor activity increases energy expenditure and drives fat oxidation, particularly in the liver.
So rather than only turning intake down, it also turns output up. That's the theoretical case for why it produces larger reductions than single or dual agonists.
What the trials found
The Phase 2 obesity trial, published in the New England Journal of Medicine, randomised 338 adults across a range of doses over 48 weeks. Participants on the highest dose saw a mean weight reduction of 24.2% — around 58 pounds across the 11 months of the study. Notably, the group had not reached a weight plateau when the trial ended, meaning the full effect hadn't been reached.
A separate substudy in participants with metabolic dysfunction-associated steatotic liver disease found liver fat reductions above 80% at the higher doses by week 24.
Retatrutide is now in TRIUMPH, Lilly's Phase 3 registrational programme, which extends beyond weight into obstructive sleep apnoea and knee osteoarthritis.
Does retatrutide cause more muscle loss?
This was a legitimate scientific concern rather than gym-floor speculation. Sustained glucagon receptor activation can reduce circulating amino acids, and lower amino acid availability could in principle blunt muscle protein synthesis. Because retatrutide is the first of these compounds to hit that receptor, the question needed answering directly.
A body composition substudy of the Phase 2 trial, published in The Lancet Diabetes & Endocrinology, used DXA scanning in 189 participants to separate fat mass from lean mass at 36 weeks. The finding: fat mass reduction substantially outpaced lean mass loss, and the proportion of lean mass lost relative to total weight lost was in line with other obesity treatments. The authors described this as reassurance that a greater share of lean tissue is not lost despite the larger total weight loss.
Read that carefully, because the word doing the work is "proportion."
The ratio holds. The total does not. If you lose 24% of your bodyweight instead of 10% at the same fat-to-lean ratio, you have lost substantially more absolute lean tissue — because you lost far more of everything.
That is the whole argument for training through it. A more effective drug doesn't reduce the need for resistance training and adequate protein. It raises it, because there is simply more weight moving and more of it can come from the wrong place.
Its regulatory status, stated plainly
Retatrutide is investigational and has not been approved by Health Canada, the FDA, or any other regulator. It remains in Phase 3 trials. There is no legal prescribing pathway for it anywhere, and the only lawful route of access is enrolment in an authorised clinical trial.
On products sold online
Unapproved compounds marketed through research-chemical suppliers are not subject to pharmaceutical manufacturing controls. Dose, purity and sterility are unverified. We don't advise on sourcing or using unapproved substances, and we'd encourage anyone considering weight-loss medication to have that conversation with a physician who can review their history and monitor them properly.
Where we can help is the part that isn't in dispute: whatever route someone takes to a calorie deficit, the training and nutrition around it determine how much muscle survives it. That part is coaching, and it's what we've done since 2012.
Retatrutide is not a fat loss drug
This gets misunderstood constantly, and the misunderstanding is what leads people into trouble.
None of these compounds burn fat directly. What they do is change the conditions you're operating in. GLP-1 and GIP activity suppresses appetite, which makes a calorie deficit sustainable in a way willpower rarely manages. Retatrutide's glucagon component does additionally raise energy expenditure and fat oxidation — so unlike the earlier drugs it works on both sides of the ledger rather than intake alone.
But both sides of the ledger are still the ledger. Every one of these drugs produces weight loss by creating an energy deficit. They don't suspend energy balance; they make achieving it far easier and far more consistent.
What the drug actually gives you is a stable, consistent environment — a deficit you can hold for months without the hunger that historically ended every attempt.
It does not decide what that deficit takes from you. That's determined by how steep you let it run, how much protein you eat, and whether anything is asking your muscle to stay. Those three things are coaching, not pharmacology.
What actually protects lean mass
Three things carry nearly all of the outcome. None are complicated. All get skipped.
Resistance training
The deciding variable. Progressive, structured lifting two to four times a week tells the body the tissue is needed. Nothing else sends that signal — cardio doesn't, walking doesn't, being active at work doesn't.
Protein intake
Roughly 1.6 to 2.2 g per kg of bodyweight daily, spread across meals. On reduced appetite this takes planning and often needs to be built around the medication's timing rather than hoped for.
A deficit that's honest
Gradual loss preserves more lean tissue than rapid loss. If the scale is dropping faster than intended, that's not a win to celebrate — it's a signal to eat more, not less.
The same drugs, with training: a different outcome entirely
A published case series followed three patients who deliberately prioritised lean-mass preservation while on semaglutide or tirzepatide. They resistance trained three to five days a week and ate 1.6–2.3 g of protein per kg of fat-free mass.
Their results, measured by DXA:
- Lost 33.0% of bodyweight — fat mass down 53.4%, lean soft tissue down 6.9%
- Lost 26.8% of bodyweight — fat mass down 61.6%, lean soft tissue up 2.5%
- Lost 13.2% of bodyweight — fat mass down 46.9%, lean soft tissue up 5.8%
Two of the three finished with more lean tissue than they started with, having lost a quarter of their bodyweight. Separately, the SEMALEAN study of 106 patients found lean mass declined early then stabilised, grip strength improved, and the prevalence of sarcopenic obesity fell from 49% to 33% over twelve months.
Same medications. Opposite body composition outcomes.
The variable that separated them wasn't the drug, the dose or the compound. It was whether anyone was lifting and eating enough protein.
The training block matters more than the training
Turning up and lifting something is better than nothing. But in a deficit, recovery capacity is reduced, and a programme built for a surplus will bury you.
What changes when you train while losing weight on medication:
- Intensity is held, volume is managed. Load is what preserves muscle. Cutting weight on the bar to chase higher reps and more sets is the opposite of what the situation calls for.
- Progression is measured differently. Holding your lifts steady while bodyweight falls is progress. Expecting personal bests in a deficit sets you up to feel like you're failing when you aren't.
- Recovery is the constraint. Less food means less capacity. Session frequency and volume get planned around that rather than around what worked when you were eating more.
- Cardio is a tool, not the plan. Piling on cardio deepens the deficit that's already doing the work. It usually costs more than it returns here.
How we work alongside your medication
We're a personal training gym, not a clinic. We don't prescribe, supply or advise on medication — that belongs with your doctor. What we do is build the half of the equation the prescription doesn't cover.
Training built for a deficit, not borrowed from a bulk
Recovery capacity falls when intake falls. A programme written for someone eating plenty will bury you. We hold intensity — load is what preserves muscle — while managing volume and frequency against what you can actually recover from on reduced food.
Protein targets that survive appetite suppression
Telling someone to eat 160 g of protein is useless when the medication has made food unappealing. We build intake around when the suppression is weakest, in formats that go down when appetite doesn't cooperate.
Progress measured properly
Scale weight is the wrong primary metric here, because it can't tell you what you lost. Strength retention across the block is a usable proxy: if your lifts hold while bodyweight falls, lean tissue is holding. If your lifts collapse, the deficit is too steep and we adjust before the damage is done.
Planning for the other side
Most people don't stay on these medications indefinitely. What you're standing on when appetite returns determines whether you hold your result. Muscle retained through the loss phase means a higher maintenance intake and something to keep.
Common questions
Do you lose muscle on GLP-1 medication?
Some lean tissue is lost in any weight-loss phase, medicated or not. The medication doesn't have a muscle-wasting mechanism — it suppresses appetite. What determines how much muscle you keep is how deep the deficit runs, how much protein you eat, and whether you're resistance training. Those three factors matter far more than which method got you into the deficit.
How much protein should I eat while on a GLP-1?
Around 1.6 to 2.2 grams per kilogram of bodyweight per day is the range that supports lean-mass retention in a deficit. The practical problem is appetite suppression — hitting that figure usually requires structuring meals deliberately and often timing them around when the medication's effect is weakest.
Can I lift weights while losing weight on medication?
You should. Resistance training is the strongest signal available that muscle tissue needs to be kept. The programme does need adjusting for reduced recovery capacity, but training through a deficit is the difference between arriving lean and arriving merely smaller.
Do you lose muscle on retatrutide?
The Phase 2 body composition substudy published in The Lancet Diabetes & Endocrinology used DXA scanning and found fat mass reduction well ahead of lean mass loss, with the proportion of lean loss to total weight loss comparable to other obesity treatments. There's no evidence of a disproportionate muscle-wasting effect.
The catch is that proportion isn't the same as amount. Retatrutide produced far larger total weight loss in trials, so the same ratio still means more absolute lean tissue lost. Resistance training and adequate protein matter more with a more effective drug, not less.
What makes retatrutide different from Ozempic or Mounjaro?
Receptor count. Semaglutide acts on GLP-1. Tirzepatide acts on GLP-1 and GIP. Retatrutide adds glucagon receptor agonism on top of both, which increases energy expenditure and fat oxidation rather than only reducing appetite. In Phase 2, the highest dose produced a mean 24.2% weight reduction over 48 weeks.
Is retatrutide available in Canada?
No. Retatrutide has not been approved by Health Canada or any other regulator and remains in Phase 3 clinical trials. There is no prescribing pathway for it. Anything sold online as retatrutide sits outside pharmaceutical manufacturing controls, with unverified dose, purity and sterility.
Do you prescribe or supply weight-loss medication?
No. We're a personal training gym, not a medical practice. Medication decisions belong with your doctor. What we do is build the training and nutrition around whatever approach you and your physician settle on, so the weight you lose is the weight you meant to lose.
Will I regain the weight if I come off the medication?
Weight regain after discontinuation is common and well documented. The variable you control is what your body looks like underneath. Muscle retained through a weight-loss phase supports a higher maintenance intake and gives you something to hold, rather than starting over from a lower baseline.
Lose the fat. Keep what you built.
If you're on weight-loss medication or considering it, the training around it decides your result. Let's build that part properly.
This page is general educational information about training and nutrition, not medical advice. Hammer Fitness does not prescribe, supply, or advise on the use of any medication. Decisions about weight-loss medication should be made with a licensed physician who can assess your individual history and monitor your treatment.
